IP Library › Granted Patent US 7,781,595
Granted Patent B2
US 7,781,595 · App. 10/572,958 · Granted Aug 24, 2010

Benzimidazole derivatives: preparation and pharmaceutical applications

Assignee: S*BIO Pte Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,781,595
App. No.
10/572,958
Granted
Aug 24, 2010
Kind
B2
Abstract

The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to benzimidazole containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with dysregulation of histone deacetylase (HDAC).

Claims (20)

1. A compound of the formula:

wherein

R 1 is selected from the group consisting of: H and unsubstituted or substituted C 1 -C 10 alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, C 4 -C 9 heterocycloalkylalkyl, arylalkyl, and heteroarylalkyl, each of which may be unsubstituted or substituted with one or more substituents independently selected from the group consisting of: halogen, ═O, ═S, —CN, —NO 2 , alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkylamino, acylamino, aminoalkyl, phenoxy, benzyloxy, alkylsulfonyl, arylsulfonyl, aminosulfonyl, —COOH, —C(O)OR 5 , —SH, and acyl;

R 2 is selected from the group consisting of: H, halogen, and unsubstituted or substituted C 1 -C 10 alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, C 4 -C 9 heterocycloalkylalkyl, arylalkyl, and heteroarylalkyl, each of which may be unsubstituted or substituted with one or more substituents independently selected from the group consisting of: halogen, ═O, ═S, —CN, —NO 2 , alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, phenoxy, benzyloxy, alkylamino, acylamino, aminoalkyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, —COOH, —C(O)OR 5 , —SH, and acyl;

R 3 is selected from the group consisting of H, C 1 -C 6 alkyl, and acyl;

X and Y are the same or different and are independently selected from the group consisting of: H, halogen, —CN, —NO 2 , —CF 3 , C 1 -C 4 alkyl, —COR 5 , —SR 6 , —OR 6 , and —NR 7 R 8 ;

R 5 is C 1 -C 4 alkyl;

R 6 is C 1 -C 4 alkyl;

R 7 and R 8 are each independently selected from the group consisting of: H, C 1 -C 4 alkyl, C 4 -C 9 cycloalkyl, C 4 -C 9 heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 wherein R 3 =H.

3. A compound according to claim 1 wherein X and Y=H.

4. A compound according to claim 1 wherein R 1 is selected from the group consisting of: H and unsubstituted or substituted hydroxyalkyl, C 1 -C 10 alkyl, heteroalkyl, arylalkyl, heteroarylalkyl, and heterocycloalkyl, each of which may be unsubstituted or substituted as defined in claim 1 .

5. The compound according to claim 1 wherein R 1 is selected from the group consisting of: H, methyl; (pyridin-3-yl)methyl; 2-hydroxy-ethyl; 2,3-di-hydroxy-propyl; and 3-hydroxy-propyl.

6. A compound according to claim 1 wherein R 2 is selected from the group consisting of H, and unsubstituted or substituted C 1 -C 10 alkyl, arylalkyl, aryl, heteroaryl, heteroalkyl, and cycloalkyl, each of which may be unsubstituted or substituted as defined in claim 1 .

7. A compound according to claim 1 wherein R 2 is selected from the group consisting of 2-phenyl-propyl, 2-phenyl-ethyl, 4-methoxy-phenyl, 4-benzyloxy-3-methoxy-phenyl, pyridin-2-yl, and pyridin-4-yl.

8. The compound of claim 1 wherein the compound is selected from compounds, and their pharmaceutically acceptable salts, selected from the group consisting of

9. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable diluent, excipient or carrier.

10. The compound of claim 1 wherein the compound is selected from compounds, and their pharmaceutically acceptable salts, selected from the group consisting of

11. The compound according to claim 1 wherein R 1 is selected from the group consisting of: 2-(piperidin-1-yl)-ethyl; 2-(pyrrolidin-1-yl )-ethyl; 2-diethylamino-ethyl; and 3-dimethylamino-2,2-dimethyl-propyl.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2012
From: S*BIO PTE LTD.
To: MEI PHARMA, INC.
Reel/Frame 029040/0361 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2006
From: CHEN, DIZHONG; DENG, WEIPING; SANGTHONGPITAG, KANDA; SONG, HONG Y.; SUN, ERIC T.; YU, NIEFANG; ZOU, YONG
To: S*BIO PTE LTD.
Reel/Frame 017940/0464 →
Continuity (3)
Provisional Application 6050421400 · Sep 22, 2003
Provisional Application 6053089000 · Dec 22, 2003
Related Publication 20070043043A1 · Feb 22, 2007